Novartis Ag (NVS) Cash from Operations (2009 - 2026)

Novartis Ag has disclosed Cash from Operations across 18 years of filings, most recently posting $5.9 billion for Q2 2026.

• In Q2 2026, Cash from Operations fell 11.73% year-over-year to $5.9 billion; the TTM figure through Jun 2026 stood at $26.4 billion (up 11.39% YoY), while the FY2025 annual figure was $19.1 billion, up 8.66% from the prior year.
• Cash from Operations came in at $5.9 billion for Q2 2026 at Novartis Ag, up from $3.7 billion in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $11.7 billion in Q4 2023 to a low of $1.6 billion in Q1 2022.
• Average Cash from Operations over 5 years is $5.6 billion, with a median of $5.1 billion recorded in 2023.
• Year-over-year, Cash from Operations jumped 138.7% in 2022 and tumbled 38.83% in 2024.
• Over 5 years, Cash from Operations stood at $9.3 billion in 2022, then climbed by 25.91% to $11.7 billion in 2023, then plunged by 38.83% to $7.1 billion in 2024, then jumped by 44.38% to $10.3 billion in 2025, then tumbled by 42.94% to $5.9 billion in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were $5.9 billion in Q2 2026, $3.7 billion in Q1 2026, and $10.3 billion in Q4 2025.